Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors

(19)

(11)

EP 1 308 158 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION

(48)	Corrigendum issued on:
	17.12.2003 Bulletin 2003/51

(43)	Date of publication:
	07.05.2003 Bulletin 2003/19

(21)	Application number: 02257552.6

(22)	Date of filing: 31.10.2002

(51)	International Patent Classification (IPC)⁷: A61K 31/415, A61P 29/00, C07D 401/04, C07D 401/14, C07D 405/14, C07D 231/38

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

02.11.2001 US 335738 P

(71)	Applicant: Pfizer Products Inc.
	Groton, Connecticut 06340 (US)

(72)	Inventors:
	Sakya, S., c/oPfizer Global Research and Develop. Connecticut 06340 (US) Rast, B., c/oPfizer Global Research and Develop. Connecticut 06340 (US)

(74)	Representative: Motion, Keith Robert et al
	Pfizer Limited Patents Department Ramsgate Road Sandwich, Kent CT13 9NJ Sandwich, Kent CT13 9NJ (GB)

(54)	Sulfonylaryl- and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors

(57) The present invention relates to hydrazinyl and nitrogen oxide pyrazoles of the formula I: wherein the ring of the formula (R⁵)-A-(SO_mR⁴), m, X, R¹ through R⁵ are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.